Adjuvant Anti-HER2 Therapy Treatment-Related Amenorrhea and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

摘要

BackgroundIn premenopausal patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer, the gonadotoxicity of trastuzumab and lapatinib remains largely uncertain, and the prognostic effect of treatment-related amenorrhea (TRA) is unknown.